General Overview of our Research

Radiochemistry Laboratory

The radiochemistry laboratory has been designed to perform services to the pharmaceutical companies and research groups and to develop basic and applied research projects led by internal investigators.

   

In order to accomplish the specific law as category II radioactive facility as well as the specific regulations regarding radiopharmaceutical laboratories, the radiochemistry area is divided in different dependencies:

a. Radioactive isotopes production area: The bunker with the cyclotron and some rooms for the technical equipment are included in this area.

b. Radiotracers production area: The laboratory for the manufacture of radiotracers for research, the laboratory for the production of radiopharmaceuticals for human use, the quality control laboratory for radiopharmaceuticals for human use, the storage room, the packaging room and the changing rooms are included in this area.

       

Nuclear Imaging Laboratory (PET/SPECT)

The nuclear imaging laboratory is a pre-clinical platform dedicated to in vivo nuclear imaging in small animals such as rats and mice. It offers state-of-the-art imaging resources in Positron Emission Tomography (PET), Single Photon Emission Computerized Tomography (SPECT), Computerized Tomography (CT) and Optical Tomography.

The lab is designed to perform in vivo studies from various imaging modalities in an interleaved fashion from the same animal. The combination of these potent and non-invasive imaging techniques facilitates performing multimodal approaches to biological, physiological and medical problems, obtaining images with significant functional and anatomical information. The platform is furthermore equipped with an autoradiography system for end point-high resolution nuclear imaging.

   


Radiochemistry and Nuclear Imaging research group by Dr. Jordi Llop, is focusing on (i) developing strategies to radiolabel small molecules, macromolecules (peptides, proteins, polymers) and nanoparticles, characterize their pharmacokinetic properties, and evaluate their suitability as therapeutic and/or diagnostic agents; and (ii) investigate biological processes underlying disease (e.g. ischemia, Parkinson disease, Alzheimer disease, multiple sclerosis) using combined imaging modalities.